BioTrends Research Group, one of the world's leading research and
advisory firms for specialized biopharmaceutical issues, finds that,
although Vertex's (News - Alert) Incivek (telaprevir) and Merck's Victrelis
(boceprevir) have been much needed advances for the treatment of
genotype 1 hepatitis C (HCV) patients, there is still an unmet need for
treating these patients. Nearly all of the surveyed physicians agree
that the protease inhibitors are important advances for the treatment of
HCV and will continue to be an important option for prior failures and
partial responders; however, 84 percent of physicians also agree that
there is still a need for alternative therapies to treat HCV.
Furthermore, gastroenterologists, hepatologists and infectious disease
(ID) specialists rank the unmet need for new therapy options to treat
HCV as greater than for any other typical gastroenterologist-,
hepatologist- or ID-treated condition, based on the recently published TreatmentTrends®:
Hepatitis C (US) report.
Despite slightly higher rates of discontinuation, due primarily to
patient intolerability, physicians are currently using Incivek in a
greater proportion of their genotype 1 HCV patients than they are using
Victrelis. Moreover, surveyed physicians rate Incivek as significantly
outperforming Victrelis on the top four most important efficacy
attributes; Incivek also rates significantly higher than Victrelis on
overall physician satisfaction and overall performance.
Hepatitis C (US) report also reveals that surveyed
gastroenterologists, hepatologists or ID specialists do not anticipate
using any products that are not currently available in the treatment of
HCV in the next six months for their genotype 1 patients, indicating
that they do not think agents in development will be available, or, if
available they will not use them within the next six months.
Nevertheless, approximately half of surveyed physicians report that they
are beginning to 'warehouse' (intentionallydelay treatment) certain HCV
patients until new interferon-free regimens become available. In
addition, nearly half of these physicians also report that many of their
HCV patients are denying treatment in anticipation of emerging
interferon-free regimens in development.
With regard to products in development, Bristol Myers Squibb's
daclatasvir (BMS-790052) and Gilead's sofosbuvir (GS-7977) garnered the
highest degree of familiarity and interest for use in HCV, according to
report respondents. When rating which agents in late stage development
will bring the most value to their practice, surveyed physicians select
sofosbuvir (GS-7977) as most valuable, followed by daclatasvir
(BMS-790052), Tibotec / Medivir's simeprevir (TMC (News - Alert)-435), and Boehringer
Ingelheim's faldaprevir (BI201335).
Hepatitis C (US) is a biannual syndicated primary
market research report series that provides a comprehensive view of the
current and expected future management of HCV, with a focus on protease
inhibitor treatment. The survey was fielded in late September / early
October, prior to the AASLD's 2012 Annual Liver Meeting. The study
included 51 gastroenterologists, 25 hepatologists, and 24 infectious
disease specialists. TreatmentTrends®:
Hepatitis C (US) covers treatment approaches, including the use
of triple therapy for the treatment of HCV, as well as attitudes and
perceptions toward the treatment brands, advantages and disadvantages of
these agents, ideal patient types, barriers to growth, and expected
future use. In addition, respondents were queried about their awareness
of and interest in late stage products in development for the treatment
Specific analysis and trending of the Incivek and Victrelis launches
over the past year can be found in LaunchTrends:
Incivek and Victrelis, Wave 4, published in June 2012. Patient
level audit analysis of hepatitis C patients is covered in ChartTrends®:
Hepatitis C in the U.S., published July 2012. And finally the
patient perspective and role of the patient in treatment selection is
analyzed in PatientTrends®:
Hepatitis C, publishing in December 2012.
About BioTrends Research GroupBioTrends Research Group
provides syndicated and custom primary market research to pharmaceutical
manufacturers competing in clinically evolving, specialty pharmaceutical
markets. For information on BioTrends publications and research
capabilities, please contact us at (610) 321-9400 or www.bio-trends.com.
BioTrends is a Decision Resources Group company.
About Decision Resources GroupDecision Resources Group is a
cohesive portfolio of companies that offers best-in-class, high-value
information and insights on important sectors of the healthcare
industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may
be trademarks of their respective holders.
[ Back To SIP Trunking Home's Homepage ]